Ainos, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation TX
Business Address 3050 POST OAK BLVD,, HOUSTON, TX, 77056
Mailing Address 3050 POST OAK BLVD,, HOUSTON, TX, 77056
Phone (281) 898-6586
Fiscal Year End 1231
EIN 751974352
Financial Overview
FY2024 FY
$122K
Revenue
-$13.77M
Net Income
$31.84M
Total Assets
$13.30M
Total Liabilities
$3.89M
Cash & Equivalents
$-1.56
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D/A Beneficial ownership amendment | January 30, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 29, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
| 8-K Current report of material events | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 31, 2025 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | November 28, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | November 28, 2025 | View on SEC |
Insider Trading
SELL 1 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.